Abbott India Partners with Takeda to Launch Innovative GERD Therapy

Abbott India has entered into a non-exclusive patent license agreement with Takeda Pharmaceuticals to bring Vonoprazan, a novel gastrointestinal therapy, to the Indian market under the brand name Vonefi. Vonoprazan, a potassium competitive acid blocker (PCAB), offers a breakthrough treatment for severe acid-related conditions, such as reflux esophagitis, with the convenience of a once-daily dose.

Traditional treatments for reflux esophagitis, a condition within the gastroesophageal reflux disease (GERD) category, often require multiple doses, particularly in severe cases. Vonoprazan's innovative approach aims to simplify treatment, improving patient adherence and overall management of the condition.

This agreement allows Abbott India, a key player in gut health solutions, to extend access to Vonoprazan to a broader patient base across the country. Abbott India’s portfolio spans diagnostics, medical devices, nutrition, and branded generics, contributing to its leading position in the healthcare industry.